Early research shows promise for therapeutics that delay Type 2 Diabetes
Vanderbilt researchers have discovered a unique pathway that initiates islet β cell inflammation-a hallmark of type 2 diabetes-putting them a step closer to developing targeted therapeutics for the disease that affects one in 10 Americans. The article, "RIPK3-mediated inflammation is a conserved β-cell response to ER stress" was published in the journal Science Advances on Dec.